P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation
Michael S. Isakoff,Courtney G. Sansam,Pablo Tamayo,Aravind Subramanian,Julia A. Evans,Christine M. Fillmore,Xi Wang,Jaclyn A. Biegel,Scott L. Pomeroy,Jill P. Mesirov,Charles W. M. Roberts +10 more
TL;DR: It is demonstrated that the tumor suppressor activity of Snf5 depends on its regulation of cell cycle progression; Snf 5 inactivation leads to aberrant up-regulation of E2F targets and increased levels of p53 that are accompanied by apoptosis, polyploidy, and growth arrest.
Journal ArticleDOI
Microarray data mining: facing the challenges
TL;DR: The different patterns of gene expression following carefully tuned biological programs, according to tissue type, developmental stage, environment and genetic background account for the huge variety of different cells states and types.
Journal ArticleDOI
High-throughput Phenotyping of Lung Cancer Somatic Mutations
Alice H. Berger,Alice H. Berger,Angela N. Brooks,Angela N. Brooks,Xiaoyun Wu,Yashaswi Shrestha,Candace R. Chouinard,Federica Piccioni,Mukta Bagul,Atanas Kamburov,Atanas Kamburov,Marcin Imielinski,Marcin Imielinski,Larson Hogstrom,Cong Zhu,Xiaoping Yang,Sasha Pantel,Ryo Sakai,Jacqueline Watson,Jacqueline Watson,Nathan O. Kaplan,Joshua D. Campbell,Joshua D. Campbell,Shantanu Singh,David E. Root,Rajiv Narayan,Ted Natoli,David L. Lahr,Itay Tirosh,Pablo Tamayo,Gad Getz,Gad Getz,Bang Wong,John G. Doench,Aravind Subramanian,Todd R. Golub,Todd R. Golub,Matthew Meyerson,Matthew Meyerson,Jesse S. Boehm +39 more
TL;DR: Among these impactful variants are rare somatic, clinically actionable variants including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and multiple BRAF variants, demonstrating that rare mutations can be functionally important in cancer.
Journal ArticleDOI
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit
Zehua Zhu,Amir Reza Aref,Travis J. Cohoon,Thanh U. Barbie,Yu Imamura,Shenghong Yang,Susan Moody,Rhine R. Shen,Anna C. Schinzel,Tran C. Thai,Jacob B. Reibel,Pablo Tamayo,Jason T. Godfrey,Zhi Rong Qian,Asher N. Page,Karolina Maciag,Edmond M. Chan,Whitney Silkworth,Mary T. Labowsky,Lior Rozhansky,Jill P. Mesirov,William E. Gillanders,Shuji Ogino,Nir Hacohen,Suzanne Gaudet,Michael J. Eck,Jeffrey A. Engelman,Ryan B. Corcoran,Kwok-Kin Wong,William C. Hahn,David A. Barbie +30 more
TL;DR: It is shown that the IκB kinase (IKK)-related kinases Tank-binding kinase-1 (TBK1) and IKKε promote KRAS-driven tumorigenesis by regulating autocrine CCL5 and interleukin (IL)-6 and CYT387 as a potent JAK/TBK 1/IKKε inhibitor is identified.
Journal ArticleDOI
Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4
Yin Ren,Hiu Wing Cheung,Hiu Wing Cheung,Geoffrey von Maltzhan,Amit Agrawal,Glenn S. Cowley,Barbara A. Weir,Jesse S. Boehm,Pablo Tamayo,Alison M. Karst,Joyce F. Liu,Michelle S. Hirsch,Jill P. Mesirov,Ronny Drapkin,Ronny Drapkin,David E. Root,Justin H. Lo,Valentina Fogal,Erkki Ruoslahti,William C. Hahn,Sangeeta N. Bhatia +20 more
TL;DR: A platform for the discovery and initial validation of cancer targets, composed of a systematic effort to identify amplified and essential genes in human cancer cell lines and tumors partnered with a novel modular delivery technology.